Role of collagen deposition in lymphatic tissues and immune reconstruction during HIV-1 and SIV infections

Current HIV/AIDS Reports

Volumn 6, Issue 1, 2009, Pages 29-35

  Estes, Jacob D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COLLAGEN; TRANSFORMING GROWTH FACTOR BETA1;

BLOOD; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE SYSTEM; LUNG FIBROSIS; LYMPHOID TISSUE; NONHUMAN; POPULATION SIZE; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; TISSUE INJURY; TREATMENT DURATION; VIRUS INFECTION; ADULT; ANIMAL; CHILD; FIBROSIS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOLOGY; METABOLISM; MONKEY DISEASE; PATHOGENICITY; PATHOLOGY; T LYMPHOCYTE; VIROLOGY;

ADULT; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; CHILD; COLLAGEN; FIBROSIS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LYMPHOID TISSUE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES;

EID: 61449243795     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-009-0005-0     Document Type: Review

References (52)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS): 2006 Report on the Global AIDS Epidemic 2006. Geneva: UNAIDS; 2006.
2. Burgoyne RW, Tan DH: Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): a balancing act. J Antimicrob Chemother 2008, 61:469-473.
3. Martin JC, Soriano V, Jimenez-Nacher I, et al.: Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. Clin Microbiol Infect 2001, 7:678-681.
4. Gea-Banacloche JC, Clifford Lane H: Immune reconstitution in HIV infection. AIDS 1999, 13(Suppl A):25-38.
5. Baker JV, Peng G, Rapkin J, et al.: Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008, 48:541-546.
6. Barbaro G, Barbarini G: HIV infection and cancer in the era of highly active antiretroviral therapy. Oncol Rep 2007, 17:1121-1126.
7. Engels EA, Biggar RJ, Hall HI, et al.: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008, 123:187-194.
8. Engels EA, Pfeiffer RM, Goedert JJ, et al.: Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006, 20:1645-1654.
9. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007, 370:59-67.
10. Lewden C, Salmon D, Morlat P, et al.: Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005, 34:121-130.
11. Palefsky JM, Holly EA, Efirdc JT, et al.: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005, 19:1407-1414.
12. O'Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996, 334:426-431.
13. Egger M, May M, Chene G, et al.: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
14. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998, 280:78-86.
15. Dybul M, Fauci AS, Bartlett JG, et al.: Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002, 137:381-433.
16. Yeni PG, Hammer SM, Carpenter CC, et al.: Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002, 288:222-235.
17. Bailey AC, Fisher M: Current use of antiretroviral treatment. Br Med Bull 2008, 87:175-192.
18. + T-cell compartment during long-term HAART.
19. Hein WR: Organization of mucosal lymphoid tissue. Curr Top Microbiol Immunol 1999, 236:1-15.
20. Westermann J, Pabst R: Lymphocyte subsets in the blood: a diagnostic window on the lymphoid system? Immunol Today 1990, 11:406-410.
21. Brenchley JM, Price DA, Douek DC: HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006, 7:235-239.
22. Brenchley JM, Schacker TW, Ruff LE, et al.: CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200:749-759.
23. Clayton F, Snow G, Reka S, Kotler DP: Selective depletion of rectal lamina propria rather than lymphoid aggregate CD4 lymphocytes in HIV infection. Clin Exp Immunol 1997, 107:288-292.
24. Guadalupe M, Reay E, Sankaran S, et al.: Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003, 77:11708-11717.
25. Li Q, Duan L, Estes JD, et al.: Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434:1148-1152.
26. Mattapallil JJ, Douek DC, Hill B, et al.: Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1097.
27. Vajdy M, Veazey R, Tham I, et al.: Early immunologic events in mucosal and systemic lymphoid tissues after intrarectal inoculation with simian immunodeficiency virus. J Infect Dis 2001, 184:1007-1014.
28. + T-cell reconstitution in the gastrointestinal mucosa in most patients despite immune reconstitution in the peripheral blood.
29. + T cells in the GALT of HIV-infected individuals who had received 4.8 to 9.9 years of effective HAART showed higher frequencies of HIV infection in GALT compared with peripheral blood mononuclear cells in patients with undetectable HIV plasma viral loads.
30. + T-cell restoration of the mucosal immune system during therapy.
31. + T cells in Peyer's patches.
32. George MD, Reay E, Sankaran S, Dandekar S: Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 2005, 79:2709-2719.
33. Verhoeven D, Sankaran S, Silvey M, Dandekar S: Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol 2008, 82:4016-4027.
34. O'Murchadha MT, Wolf BC, Neiman RS: The histologic features of hyperplastic lymphadenopathy in AIDS-related complex are nonspecific. Am J Surg Pathol 1987, 11:94-99.
35. Estes JD, Wietgrefe S, Schacker T, et al.: Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 2007, 195:551-561. Nonhuman primate study showing that the mechanism of early and progressive collagen deposition in LTs results from TGF-β expression on Tregs.
36. Schacker TW, Brenchley JM, Beilman GJ, et al.: Lymphatic tissue fibrosis is associated with reduced numbers of naive CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006, 13:556-560.
37. Schacker TW, Nguyen PL, Beilman GJ, et al.: Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002, 110:1133-1139.
38. Schacker TW, Reilly C, Beilman GJ, et al.: Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4 cell count. AIDS 2005, 19:2169-2171.
39. Tsakraklides V, Tsakraklides E, Good RA: An autopsy study of human axillary lymph node histology. Am J Pathol 1975, 78:7-22.
40. Taniguchi I, Murakami G, Sato A, et al.: Lymph node hyalinization in elderly Japanese. Histol Histopathol 2003, 18:1169-1180.
41. Pahlavani MA, Richardson A, Cheung HT: Age-dependent changes of the mesenteric lymph node of Fischer F344 rats: morphological and histometric analysis. Mech Ageing Dev 1987, 39:137-146.
42. Cavert W, Notermans DW, Staskus K, et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964.
43. Zhang ZQ, Notermans DW, Sedgewick G, et al.: Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A 1998, 95:1154-1159.
44. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
45. Border WA, Ruoslahti E: Transforming growth factor-beta in disease: the dark side of tissue repair. J Clin Invest 1992, 90:1-7.
46. Mauviel A: Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol Med 2005, 117:69-80.
47. Verrecchia F, Mauviel A: Transforming growth factor-beta and fibrosis. World J Gastroenterol 2007, 13:3056-3062.
48. Estes JD, Li Q, Reynolds MR, et al.: Premature induction of an immunosuppressive regulatory T cell response during acute simian immunodeficiency virus infection. J Infect Dis 2006, 193:703-712.
49. Azuma A, Nukiwa T, Tsuboi E, et al.: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047.
50. Nagai S, Hamada K, Shigematsu M, et al.: Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002, 41:1118-1123.
51. Nicod LP: Pirfenidone in idiopathic pulmonary fibrosis. Lancet 1999, 354:268-269.
52. Raghu G, Johnson WC, Lockhart D, Mageto Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase II study. Am J Respir Crit Care Med 1999, 159:1061-1069.